TY - JOUR
T1 - Association of Statin Therapy and Risks of Cholelithiasis, Biliary Tract Diseases, and Gallbladder Procedures
T2 - Retrospective Cohort Analysis of a US Population
AU - Martin, Donald
AU - Schmidt, Robert
AU - Mortensen, Eric M.
AU - Mansi, Ishak
N1 - Publisher Copyright:
© 2015, © The Author(s) 2015.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Background: Gallstone disease is a leading cause of morbidity in Western countries and carries a high economic burden. Statin medications decrease hepatic cholesterol biosynthesis and may, therefore, lower the risk of cholesterol cholelithiasis by reducing the cholesterol concentration in the bile. Population-based evidence, however, is sparse. Objective: To assess the risk of gallbladder diseases among statin users compared with nonusers in an American patient cohort. Methods: We performed a retrospective cohort study of patients enrolled in the San Antonio Tricare health system using data between October 2003 and March 2012. We defined 2 groups: statin users (use for 90 days or greater) and nonusers (no prior statin). A propensity score based on 82 variables was generated to match statin users and nonusers 1:1. Outcomes included incidence of cholelithiasis, biliary tract diseases, and gallbladder procedures. Results: A total of 43 438 patients were identified; 13 626 (31.4%) were statin users, and 29 812 (68.6%) were nonusers. We matched 6342 pairs of statin users and nonusers based on propensity score. The odds ratios (ORs) in statin users in comparison to nonusers were similar for cholelithiasis (OR = 0.86; 95% CI = 0.73, 1.02), biliary tract disease (OR = 0.85; 95% CI = 0.67-1.08), and gall bladder procedures (OR = 0.85; 95% CI = 0.69, 1.04). Conclusions: Statin use was not significantly associated with either an increased or decreased risk of cholelithiasis or gallbladder disease.
AB - Background: Gallstone disease is a leading cause of morbidity in Western countries and carries a high economic burden. Statin medications decrease hepatic cholesterol biosynthesis and may, therefore, lower the risk of cholesterol cholelithiasis by reducing the cholesterol concentration in the bile. Population-based evidence, however, is sparse. Objective: To assess the risk of gallbladder diseases among statin users compared with nonusers in an American patient cohort. Methods: We performed a retrospective cohort study of patients enrolled in the San Antonio Tricare health system using data between October 2003 and March 2012. We defined 2 groups: statin users (use for 90 days or greater) and nonusers (no prior statin). A propensity score based on 82 variables was generated to match statin users and nonusers 1:1. Outcomes included incidence of cholelithiasis, biliary tract diseases, and gallbladder procedures. Results: A total of 43 438 patients were identified; 13 626 (31.4%) were statin users, and 29 812 (68.6%) were nonusers. We matched 6342 pairs of statin users and nonusers based on propensity score. The odds ratios (ORs) in statin users in comparison to nonusers were similar for cholelithiasis (OR = 0.86; 95% CI = 0.73, 1.02), biliary tract disease (OR = 0.85; 95% CI = 0.67-1.08), and gall bladder procedures (OR = 0.85; 95% CI = 0.69, 1.04). Conclusions: Statin use was not significantly associated with either an increased or decreased risk of cholelithiasis or gallbladder disease.
KW - cholelithiasis
KW - cholesterol
KW - statins
UR - http://www.scopus.com/inward/record.url?scp=84958752228&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958752228&partnerID=8YFLogxK
U2 - 10.1177/1060028015622649
DO - 10.1177/1060028015622649
M3 - Article
C2 - 26706861
AN - SCOPUS:84958752228
SN - 1060-0280
VL - 50
SP - 161
EP - 171
JO - Annals of Pharmacotherapy
JF - Annals of Pharmacotherapy
IS - 3
ER -